Navigation Links
Cardiac Dimensions Announces First Patient Treated in TITAN II Clinical Trial
Date:10/11/2011

KIRKLAND, Wash., Oct. 11, 2011 /PRNewswire/ -- Cardiac Dimensions®, Inc. today announced the first patient has been enrolled and successfully treated in the TITAN II clinical trial, a follow-up to the landmark TITAN clinical trial of the Company's CARILLON® Mitral Contour System. TITAN II is a prospective, single-arm clinical trial initiated to further evaluate an enhanced version of the CARILLON system, a novel therapy for treating heart failure patients suffering from functional mitral regurgitation (FMR).

During TITAN II, 30 patients across five sites will be implanted with the CARILLON system and subsequently followed for a one-year period. The initial 53-patient TITAN clinical trial demonstrated significant relief from FMR and improvements in functional capacity and quality of life compared to a contemporaneously-enrolled control group. The initial trial also demonstrated a low 30-day adverse event rate of 1.9 percent.

"We could not be more pleased with the results that were established as part of the initial TITAN clinical trial," stated Rick Stewart, President and Chief Executive Officer of Cardiac Dimensions. "The data demonstrated an exceptionally low major adverse event profile while showing significant improvement in functional capacity and quality of life. Our investigators believe that the early and sustained improvement in parameters indicative of reverse cardiac remodeling in this severely ill patient population was also a clinically significant finding.  They are eager to further their understanding of this process through the TITAN II trial."

TITAN II investigator Professor Dr. Michael Haude of Lukaskrankenhaus in Neuss, Germany, commented: "We are excited to be involved in the TITAN II study, which comes on the heels of the landmark TITAN trial. This first patient presented with severe FMR secondary to advanced heart failure, placing him at significant risk f
'/>"/>

SOURCE Cardiac Dimensions, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cytokinetics announces fundamental research in cardiac myosin activation in the journal Science
2. SYNARC Engages Dr. Peter Milner for Cardiac Imaging Services and Solutions
3. Three Top 20 Pharmaceutical Companies Select iCardiac as Preferred Vendor
4. Another Top 10 Pharmaceutical Company Awards Cardiac Safety Study to iCardiac
5. Leading Global CRO Selects iCardiac as Preferred Vendor
6. Another Top Five Pharmaceutical Company Selects iCardiac as Preferred Provider of ECG Core Lab Services
7. Global Pharmaceutical Company Awards Comprehensive Cardiac Safety Study to iCardiac
8. New Multicenter Study Finds That Cardiac Function Measured During Stress Testing With Cheetah Medicals BIOREACTANCE(R) Noninvasive Technology Offers New Insights Into Heart Failure
9. Leading Biotechnology Company Awards Phase III Cardiac Safety Study to iCardiac
10. Top 15 Pharmaceutical Company Awards Cardiac Safety Study to iCardiac
11. OrbusNeichs Genous(TM) Bio-engineered R stent(TM) is Feasible in Patients Requiring Undeferrable Non-Cardiac Surgery, International Journal of Cardiology Publication Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (PRWEB) January 15, 2014 AudioNotch is ... new therapy for the treatment of tinnitus. Patients listen ... frequency, and over a period of weeks to months, their ... Therapy in two forms: Notched Music and Notched White Noise. ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of strategic ... business, and media events in the United States ... associate Virginia Cox , JD, is returning to the firm,s ... Cox re-joins 3D after more than two years of service ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management software, today ... In this role, Michelle will work with current and potential ... development of iLab products. Her main goal will be to ... scientific community by offering the most advanced, user-friendly, and high-impact ...
(Date:1/14/2014)... January 13, 2014 Bob Hainsey, a ... than 20 years in the industry, has joined ... Hainsey will serve as the society’s Science and Technology ... join SPIE as our Technology Strategist, further strengthening the ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... -- After announcing last April a method for ... cylinders only a few atoms thick, a Duke ... process to create exclusively semiconducting versions of these ... way for manufacturing reliable electronic nanocircuits at the ...
... , ... Englewood, CO (PRWEB) January 21, 2009 -- ... (OTJ), has announced new solutions for human resource and recruitment professionals ... geographically localized markets. , , , , ,OTJ currently powers online ...
... in Diabetes Drug TherapyHARTFORD, Conn., Jan. 21 ... of certain genes in vascular and energy pathways ... retention) in patients taking the thiazolidinedione (TZD) drugs ... from Joslin Diabetes Center Affiliate at The Hospital ...
Cached Biology Technology:Semiconducting nanotubes produced in quantity at Duke 2Semiconducting nanotubes produced in quantity at Duke 3onTargetjobs Offers Employers New Recruitment Solutions to Reach Local Career Candidates 2Cardiovascular Side Effects of Pioglitazone and Rosiglitazone Linked to Vascular and Energy Pathways by Genomas Clinical Study 2
(Date:4/18/2014)... contraceptive pills in Peru found that 28 percent ... quality or falsified. Many pills released the active ... ingredient. One batch had no active ingredient at ... researchers at the Georgia Institute of Technology developed ... assess suspected counterfeit drugs and then characterize their ...
(Date:4/18/2014)... to the story of how barnyard chickens came to be, ... journal Proceedings of the National Academy of Sciences . ... 200-2300 years ago in Europe, researchers report that just a ... different from the chickens we know today. , The results ... domestic chickens -- such as their yellowish skin -- only ...
(Date:4/17/2014)... 17 In the most densely forested and most ... two centuries of human needs, values and practices. Disturbances ... forests for agriculture and development, have set the stage ... Forest Service study reports. , The report Five ... management needs in the Northern United States ...
Breaking Biology News(10 mins):Counterfeit contraceptives found in South America 2Counterfeit contraceptives found in South America 3Ancient DNA offers clues to how barnyard chickens came to be 2Five anthropogenic factors that will radically alter northern forests in 50 years 2Five anthropogenic factors that will radically alter northern forests in 50 years 3
... estrogen receptors are more difficult to treat than ... Meeting 2013 demonstrates an investigational drug, Paragazole, that ... and that increases the sensitivity of these cells ... do is use triple-negative breast cancer models to ...
... identified four genes newly associated with severe childhood obesity. ... variations in severely obese children. The team found ... help to maintain protein receptors known to be involved ... targets for the development of new drugs against obesity. ...
... biologist at the Florida State University College of Medicine ... closer to understanding how life first emerged on Earth ... team produced data supporting the idea that 10 amino ... years ago were capable of forming foldable proteins in ...
Cached Biology News:Finding genes for childhood obesity 2Researcher offers clues on the origins of life 2Researcher offers clues on the origins of life 3
...
Contains L-glutamine...
...
... ZMD.358. Immunogen: Synthetic peptide ... of human mouse and rat ... human and mouse LRP5 proteins. ... controls: mouse LRP5-pSEC-tag-transfected 293T cells ...
Biology Products: